

Ben Ray Lujan

AMENDMENT NO. 1

Calendar No. _____

Purpose: To improve the requirements for making a determination of interchangeability of a biological product and its reference product.

IN THE SENATE OF THE UNITED STATES—118th Cong., 1st Sess.

S. 2840

To improve access to and the quality of primary health care, expand the health workforce, and for other purposes.

Referred to the Committee on _____ and
ordered to be printed

Ordered to lie on the table and to be printed

AMENDMENT intended to be proposed by Mr. LUJÁN

Viz:

- 1 At the appropriate place in title III, insert the fol-
- 2 lowing:
- 3 **SEC. 3 ____ . BIOSIMILAR BIOLOGICAL PRODUCTS.**
- 4 (a) IN GENERAL.—Section 351(k) of the Public
- 5 Health Service Act (42 U.S.C. 262(k)) is amended—
- 6 (1) in the subsection heading, by striking “OR
- 7 INTERCHANGEABLE”;
- 8 (2) in paragraph (2)—
- 9 (A) by striking subparagraph (B);
- 10 (B) by redesignating clauses (ii) and (iii)
- 11 of subparagraph (A) as subparagraphs (B) and

1 (C), respectively, and adjusting the margins ac-
2 cordingly;

3 (C) in subparagraph (A)—

4 (i) in clause (i), by redesignating sub-
5 clauses (I) through (V) as clauses (i)
6 through (v), respectively, and adjusting the
7 margins accordingly;

8 (ii) in clause (i), as so redesignated by
9 clause (i) of this subparagraph, by redesi-
10 gnating items (aa) through (cc) as sub-
11 clauses (I) through (III), respectively, and
12 adjusting the margins accordingly; and

13 (iii) by striking “(A) IN GENERAL”
14 and all that follows through “An applica-
15 tion submitted under this subsection shall
16 include information” and inserting the fol-
17 lowing:

18 “(A) IN GENERAL.—An application sub-
19 mitted under this subsection shall include infor-
20 mation”;

21 (D) in subparagraph (B), as so redesi-
22 gnated by subparagraph (C) of this paragraph,
23 by striking “clause (i)(I)” and inserting “sub-
24 paragraph (A)(i)”; and

1 (E) in subparagraph (C), as so redesign-
2 nated by subparagraph (C) of this paragraph,
3 by redesignating subclauses (I) through (III) as
4 clauses (i) through (iii), respectively, and by ad-
5 justing the margins accordingly;

6 (3) by amending paragraph (4) to read as fol-
7 lows:

8 “(4) INTERCHANGEABILITY.—A biological prod-
9 uct licensed under this subsection shall be deemed to
10 be interchangeable with the reference product.”;

11 (4) by striking paragraph (6); and

12 (5) in paragraph (8)(D)—

13 (A) in clause (i), by striking “class; and”
14 and inserting “class.”;

15 (B) by striking clause (ii); and

16 (C) by striking “description of—” and all
17 that follows through “criteria that the Sec-
18 retary” and inserting “description of the cri-
19 teria that the Secretary”.

20 (b) CONFORMING AMENDMENTS.—

21 (1) Section 351(i)(3) of the Public Health Serv-
22 ice Act (42 U.S.C. 262(i)(3)) is amended by striking
23 “that is shown to meet the standards described in
24 subsection (k)(4)” and inserting “licensed under
25 subsection (k)”.

1 (2) Section 352A of the Public Health Service
2 Act (42 U.S.C. 263-1) is amended by striking “and
3 interchangeable biosimilar biological products” each
4 place it appears.

5 (3) Section 744G(14) of the Federal Food,
6 Drug, and Cosmetic Act (21 U.S.C. 379j-51(14)) is
7 amended by striking “, including a supplement re-
8 questing that the Secretary determine that the bio-
9 similar biological product meets the standards for
10 interchangeability described in section 351(k)(4) of
11 the Public Health Service Act”.

12 (4) By amending subsection (l) of section 505B
13 of the Federal Food, Drug, and Cosmetic Act (21
14 U.S.C. 355c) to read as follows:

15 “(1) BIOSIMILAR BIOLOGICAL PRODUCTS.—A biologi-
16 cal product for which an application is submitted under
17 section 351(k) of the Public Health Service Act shall be
18 considered to have a new active ingredient for purposes
19 of this section, except that a pediatric assessment shall
20 not be required for a claimed indication in a relevant pedi-
21 atric population if the assessment would involve—

22 “(1) a condition of use that has not been pre-
23 viously approved for the reference product; or

1 “(2) a dosage form, strength, or route of ad-
2 ministration that differs from that of the reference
3 product.”.

4 (c) APPLICATION.—The amendment made by sub-
5 section (a)(4) to strike paragraph (6) of section 351(k)
6 of the Public Health Service Act (42 U.S.C. 262(k)) shall
7 apply only with respect to applications approved under
8 section 351(k) of such Act on or after the date of enact-
9 ment of this Act. Any period of exclusivity granted under
10 section 351(k)(6) of such Act with respect to an applica-
11 tion approved under such section 351(k) before the date
12 of enactment of this Act shall apply in accordance with
13 paragraph (6) of such section 351(k), as in effect on the
14 day before the date of enactment of this Act.